EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Small molecules targeting different cellular pathologies for the treatment of amyotrophic lateral sclerosis

Mohamed F Elmansy iD, Cory T Reidl, Mizzanoor Rahaman iD, P Hande Özdinler iD, Richard B Silverman iD

Medicinal Research Reviews · 2023-11 · 43 (6) · 2260-2302

DOI: 10.1002/med.21974 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 26.05.2023. Verfasst von Mohamed F Elmansy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Department of Molecular Biosciences, Chemistry of Life Processes Institute, Center for Developmental Therapeutics, Northwest…. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 220 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease in which the motor neuron circuitry displays progressive degeneration, affecting mostly the motor neurons in the brain and in the spinal cord. There are no effective cures, albeit three drugs, riluzole, edaravone, and AMX0035 (a combination of sodium phenylbutyrate and taurursodiol), have been approved by the Food and Drug Administration, with limited improvement in patients. There is an urgent need to build better and more effective treatment strategies for ALS. Since the disease is very heterogenous, numerous approaches have been explored, such as targeting genetic mutations, decreasing oxidative stress and excitotoxicity, enhancing mitochondrial function and protein degradation mechanisms, and inhibiting neuroinflammation. In addition, various chemical libraries or previously identified drugs have been screened for potential repurposing in the treatment of ALS. Here, we review previous drug discovery efforts targeting a variety of cellular pathologies that occur from genetic mutations that cause ALS, such as mutations in SOD1, C9orf72, FUS, and TARDP‐43 genes. These mutations result in protein aggregation, which causes neuronal degeneration. Compounds used to target cellular pathologies that stem from these mutations are discussed and comparisons among different preclinical models are presented. Because the drug discovery landscape for ALS and other motor neuron diseases is changing rapidly, we also offer recommendations for a novel, more effective, direction in ALS drug discovery that could accelerate translation of effective compounds from animals to patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisNeurodegenerative DiseasesAnimalsHumansDisease Models, AnimalMotor NeuronsPhenylbutyrates

Stichwörter der Autor:innen

amyotrophic lateral sclerosiscellular pathologiesgene mutationsinhibitionprotein aggregation

Substanzen

sodium phenylbutyrate and taurursodiolPhenylbutyrates

Autor:innen und Institutionen

  • Department of Chemistry, Department of Molecular Biosciences, Chemistry of Life Processes Institute, Center for Developmental Therapeutics, Northwestern University, Evanston, Illinois, USA.
  • Department of Organometallic and Organometalloid Chemistry, National Research Centre, Cairo, Egypt.
  • Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.

ORCID-Profile: Mohamed F Elmansy, Mizzanoor Rahaman, P Hande Özdinler, Richard B Silverman

Förderung

  • NIA NIH HHS
  • National Institutes of Health

Zitieren

APA

Elmansy, M. F., Reidl, C. T., Rahaman, M., Özdinler, P. H., & Silverman, R. B. (2023). Small molecules targeting different cellular pathologies for the treatment of amyotrophic lateral sclerosis. Medicinal Research Reviews, 43(6), 2260-2302. https://doi.org/10.1002/med.21974

Vancouver

Elmansy MF, Reidl CT, Rahaman M, Özdinler PH, Silverman RB. Small molecules targeting different cellular pathologies for the treatment of amyotrophic lateral sclerosis. Medicinal Research Reviews. 2023;43(6):2260-2302. doi:10.1002/med.21974

BibTeX
@article{Elmansy2023,
  author = {Elmansy, Mohamed F and Reidl, Cory T and Rahaman, Mizzanoor and Özdinler, P Hande and Silverman, Richard B},
  title = {Small molecules targeting different cellular pathologies for the treatment of amyotrophic lateral sclerosis},
  journal = {Medicinal Research Reviews},
  year = {2023},
  volume = {43},
  number = {6},
  pages = {2260--2302},
  doi = {10.1002/med.21974}
}
Kostenlos starten →